AnazaoHealth Corporation, Las Vegas, NV
Is AnazaoHealth Corporation an FDA-registered 503B outsourcing facility?
Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names AnazaoHealth Corporation in Las Vegas, NV, first registered Sep 23, 2014 and most recently registered Dec 30, 2025. FDA lists its last inspection as Aug 8, 2025, with a Form FDA 483 issued; FDA lists the action on that inspection as “Response Letter Issued 1/7/2026”.
FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.
- Location on FDA’s list
- Las Vegas, NV
- Initial registration
- Sep 23, 2014
- Most recent registration
- Dec 30, 2025
- Last inspection
- Aug 8, 2025
- Form 483 issued at last inspection
- Yes
- Recall after last inspection
- No
- Action on last inspection
- Response Letter Issued 1/7/2026
- Intends to compound sterile drugs from bulk substances
- Yes
FDA inspections and actions on record
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as Anazaohealth Corporation, Las Vegas, NV, a 503B facility, with 6 listed actions, including 4 Form 483s and 1 warning letter (2019 to 2025).
| Document | |||
|---|---|---|---|
| Aug 8, 2025 | Form 483 | 483 issued 08/08/2025 | fda.gov |
| Sep 23, 2024 | Form 483 | 483 Issued 09/23/2024 | fda.gov |
| May 2, 2023 | Regulatory meeting | Regulatory Meeting Held 05/02/2023 | Not linked by FDA |
| Jul 29, 2022 | Form 483 | 483 Issued 07/29/2022 | fda.gov |
| Aug 18, 2021 | Warning letter | Warning Letter (08/18/2021) | fda.gov |
| Sep 19, 2019 | Form 483 | 483 Issued 09/19/2019 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.
Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists AnazaoHealth Corporation, Las Vegas, NV (FEI number 3011152407), matched to this page by exact name, city and state. It lists 5 inspections: 5 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Aug 8, 2025 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3011152407 | 1278379 |
| Sep 23, 2024 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3011152407 | 1252328 |
| Jul 29, 2022 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3011152407 | 1177831 |
| Sep 19, 2019 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3011152407 | 1102395 |
| Jan 30, 2015 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3011152407 | 913271 |
Form 483s FDA has published for this site
- Aug 8, 2025: Form 483 to AnazaoHealth Corporation, published Sep 2, 2025. fda.gov
- Sep 23, 2024: Form 483 to AnazaoHealth Corporation, published Feb 7, 2025. fda.gov
- Jul 29, 2022: Form 483 to AnazaoHealth Corporation, published Nov 21, 2022. fda.gov
- Sep 19, 2019: Form 483 to AnazaoHealth Corporation, published Nov 27, 2019. fda.gov
- May 15, 2017: Form 483 to AnazaoHealth Corporation, published Jan 17, 2024. fda.gov
- Apr 28, 2017: Form 483 to AnazaoHealth Corporation, published Jan 17, 2024. fda.gov
- Jul 23, 2015: Form 483 to AnazaoHealth Corporation, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 16 numbered observations in all, across 3 inspections ending Sep 19, 2019 to Aug 8, 2025. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Jul 28, 2025 to Aug 8, 2025: 4 observations
- Firm on the cover
- AnazaoHealth Corporation, 7465 W Sunset Rd Ste 1200, Las Vegas, NV 89113-1944
- FEI number
- 3011152407
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 19701 Fairchild Irvine, CA 92612-2445
- Matched to this page by
- FEI number on the cover; linked from actions page, 503B list, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Specifically,
A. Your firm's process validation for the pellet products intended for implantation does not assess pellet-to-pellet content uniformity. According to Process Validation for Testosterone 12.5 mg Pellet Q <Redacted B4> Document Number: VAL 097, dated 3/7/2018, Process Validation for Estradiol 6 mg Pellet Q <Redacted B4>, Document Number: VAL 101, dated 7/25/2018, and Analysis of Testosterone, Estradiol, or Naltrexre by ;PLC (cGMP Release Testing), Doc <Redacted B4> Dent Number AMl-1 319, at each stage of production -<Redacted B4> -your firm pooled 4H pellets of either Testosterone 12.5 mg or Estradiol 6 mg or testmg, which yielded passing results. However, no individual pellet was tested to assess uniformity, thereby failing to demonstrate content consistency across individual units. your firm produced approximately <Redacted B4> pellet batches per <Redacted B4>".
B. ...
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
Specifically,
A. During aseptic operations, the innermost sterile packaging layer of stoppers was routinely briefly exposed to the ISO 7 environment prior to transfer into the ISO 5 Laminar Airflow Hood (LAFH), without disinfection. For example, the camera footage shows that during the production of Ascorbic Acid30mL (PF-Non-Com), Lot # 1021502, Manufactured Date <Redacted B4>I, the <Redacted B4> outer layers of the stopper packaging were cut open by an operator in the ISO 7 buffer room, and the operator working at the ISO 5 LAFH then extended his gloved hands outside the hood to pull the inner layer directly from the ISO 7 area into the ISO 5 area, exposing the inner layer to the ISO 7 environment. Your firm produced approximately <Redacted B4> sterile batches of vial products per <Redacted B4>
B. Your firm has not conducted a hold time study to support the <Redacted B4> expiration period assigned to depyrogenized glassware and utensils used in the ISO 5 aseptic processing area. ...
Observation 3
Complaint records are deficient in that they do not include the findings of the investigation and follow-up.
Specifically,
Your firm's complaint investigation procedures are inadequate as investigations consistently fail to include retain sample testing when quality-related adverse events are reported. For example:
A. A provider reported multiple complaints potentially related to insertion site infections, including tenderness, pain, swelling, and/or inflammation after using Testosterone pellets at various dosages in 2025. Your firm's investigation concluded that no deficiencies were identified for these complaints; however, no retain sample testing was performed to evaluate potential sterility, bioburden, or other quality attributes that could contribute to infection reactions.
B A provider reported that three patients experienced burning sensations following administration of Ascorbic Acid (Preserved) 500mg/mL, Lot 740667 in 2025. ...
Observation 4
Laboratory records do not include complete data derived from all tests, examinations and assay necessary to assure compliance with established specifications and standards.
Specifically,
A. Your firm does not test individual pellets for content uniformity during batch release of pellet product. Instead, your firm pools <Redacted B4> pellets from each batch for routine assay testing. For example, the batch record for Estradiol 10 mg pellet Q <Redacted B4>, Lot# 896276, manufactured on <Redacted B4> and the batch record of Testosterone 100 mg, Lot# 972948, manufactured on <Redacted B4> showed that the assay testing performed by a third-party laboratory yielded passing results in accordance with TEST AMI-1319, based on a <Redacted B4> of <Redacted B4> pellets. This practice does not evaluate the variability between individual dosage units and cannot ensure uniformity of strength as required by finished products specifications.
B. Your firm does not perform hardness testing for pellet drug products during batch release testing to ensure mechanical integrity and consistent quality of each lot produced. ...
Inspection Mar 15, 2017 to Mar 4, 2020: 9 observations
- Firm on the cover
- AnazaoHealth Corporation, 7465 W. Sunset Road, Suite 1200, CODE
- FEI number
- 3011152407
- Establishment type on the cover
- Outsourcing Facility La Vegas, NV 89113
- FDA district office on the cover
- Alameda, CA 94502
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.
Specifically, during the redacted (b) (4) re-qualification of your r edacted (b) (4) , your firm failed to maintain y our sterilizing and depyroge nation redacted (b) (4) estab lish ed in yo ur protocol for redacted (b) (4) and depyrogenation. For example, the following criteria established in your protocols were not met during the redacted (b) (4) re-qualification:
....,....-;~.... Specifically, during the redacted (b) (4) re-qualification of your redacted (b) (4) , your firm failed to maintai n your sterilizing and depyrogenation redacted (b) (4) established in your protocol for redacted (b) (4) and depyrogenation. For example, the following criteria established in your protocols were not met during the redacted (b) (4) re-qualification:
Depyrogenation for 5mL glass vials (b) (4) -None ofthe'lb>! 4>
(15) (4) to ensure adequate depyrogenation. A. November 2016 redacted (b)(4) drug solution redacted (b)(4) depyrogenation for 5 mL glass vials redacted (b)(4). ...
Observation 2
Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriat e laboratory testing.
Your firm lacks scientific justification for using red acte d (5)(4) Sterilization Validation method for steriliz ation of compounded pellet products which includes but are not limited to Testosterone, Testosterone/ Anastrozole, and
Estradiol products.
Your firm follows methods in ISO 11737 that consists of the following parts entitled re da cted (b)(4). Your firm lacks sufficient scientific justification to show this validation method is specific for your pharmaceutical pellet products.
Sterile pellet drug product batches produced for r (b ) (4 ) Jare not representative ofthe routine S terile pellet drug product batches products for redacted (b )(4) are not representativ e of the routine manufacturing batches. Your firm produces appr oximately redacted (b)(4); however, your firm’s routine manufacturing batches may produce up to redacted (b)(4).
Observation 3
Drug products failing to meet established specifications and quality control criteria are not rejected.
Specifically,
A. On 3/16/2016, we observed Pharmacy Technician redacted (b)(6) performing visual inspection of sterile injectab le drug product, MIC with Cyanocobalamin 25/50/50/1 mg per mL, 30mL vials, lot #031417-IKS-151641. Reda cted (b)(6) performed visual inspection for approximately 1.5 hours without taking any breaks. After these vi als passed visual inspection, we reviewed 9 vials from the lot and observed 2 vials appeared to have particle s or specs adhering to the inside of the glassware. This defect was confirmed by your firm’s Sterile Supe
rvisor redacted (b)(6) and redacted (b)(6) stated these vials should have been rejected per your firm’s visual inspection SOP.
In addition, we inspected Testosterone Cypionate 200mg/m L, lot #03 I 0 l7-2KS-151385, which had completed visual inspection. We observed particles in 4 vials out ofthe 2~ we, reviewed. These particles were .. confirmed by Sterile Supervisor'(b)(Sland Pharmacy Technicia.rC..<j\ccording to Sterile Supervisor<~>> <6>these vials should have been rejected per your firm's visual inspection SOP. ...
Observation 4
Employees engaged in the processing of a drug product lack the training required to perform their assigned functions.
Specifically, our review of your firm's visual inspection redacted (b) (4) reveale d the redacted (b)(4) does n ot reflect actual vials encountered during the visual inspection process. Fo r example , the redacted (b)(4) does not in clude a representative vial with a pink colored solution in an amber colored vial similar to what is observed in MIC with Cyanocobalamin injectable products and Methylcobalamin injectable products. We also observed particle s in test vials #2, 17, 23, and 52 which were labeled as controls (without particles or defects). We revi
ewed the visual inspection redacted (b)(4) results and found while some technicians were able to identify the same particles, others did not, indicating the technicians are not properly trained and fully qualified t o pe rform visual ins pection . The red acted ( b) (4) also includes redacted (b)(4) such as (b)(4).
Observation 5
Written records are not always made of investigation s into unexplained discrepancies and the failure of a batch or any of its components to meet specifications.
Specifically, we reviewed the alarm settings and temperature recording for redacted (b)(4) incubators and reda
cted (b) (4 ) on 3/22/2017 and observed the following deficiencies:
A. Your firm has not set high and low alarms for the temperature of your firm's Incubator redac ted (b)(4). The incuba tor is used to incubate environmental monitoring sam ples fro m redacted (b) (4).We reviewed the temperature
recordings for the previous year and observed on numerous occasions the incubator dropped below the redacte d (b)(4) lower limit including on 11/15/2016 when the temperature was out of range for more than 10 hours duri ng the incubation of environmental monitoring samples. Your firm has not investigated these events to ens ure the samples in the incubator are not affected.
B. Your firm's alarm settings for redacted (b)(4) are not configured to notify you when the temperature drops redacted (b)(4). The redacted (b)(4) is used to store environmental monitoring samples that are required to be incubated at redacted (b)(4). ...
Observation 6
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.
On redacted (b)(4), we observed media fill ba tch reda cted (b)(4) on a metal shelf in the hallway outside ante r
oom r edac ted (b)(4). There is no temperature probe physically close to this area and no d ocumented temperature monitoring of this hallway. Your firm does not have data to determine whether or not the media fill batch was incubated at the appropriate redacted (b)(4) temperature requirement for redacted (b)(4).
Observation 7
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically, your firm does not review the pressure differential data to ensure there were no unacceptable losses of pressure obtained during manufacturing operations in your clean rooms. Your firm only reviews alarms however your r edacted (b)(4) system is set to only redacted (b)(4). Your firm does not have any justification for choosing redacted (b)(4) as your criteria for redacted (b)(4). Specifically, your firm does not review the pressure differential data to ensure there were no unacceptable losses of pressure obtained during manufacturing operations in your clean rooms. Your firm only reviews alarms however your redacted (b)(4) system is set to only redacted (b)(4). Your firm does not have any justification for choosing redacted (b)(4) as your criteria for redacted (b)(4).
Specifically, your firm does not review the pressure differential data to ensure there were no unacceptable losses of pressure obtained during manufacturing operations in your clean rooms. Your firm only reviews alarms however your redacted (b)(4) system is set to only redacted (b)(4). ...
Observation 8
Clothing of personnel engaged in the manufacturing and processing of drug products is not appropriate for th e duties they perform.
Specifically, your firm's technicians wear sterile goggles for redacted (b)(4) prior to discarding the goggles. These goggles are sanitized with redacted (b)(4). However, your firm failed to properly validate the cleanroom goggle sanitization process. Cleanroom Goggles Sterilization Validation VAL 033 is inadequate in that samples collected were not transported to the testing laboratory within the required time frame. Redacted (b)(4). Validation samples from weeks 2 and 3 did not reach the testing laboratory within the required time frame. However, your firm accepted the results and established your cleanroom goggle sanitization time periods based on these invalid test results. Specifi ca lly, your firm's technicians wear sterile goggles for redacted (b)(4) prior to discarding the goggles. These goggles are sanitized with redacted (b)(4). However, your firm failed to properly validate the cleanroom goggle sanitization process. ...
Observation 9
Bulk drug substances used by your outsourcing facility to compound drug products are not each manufactured by an establishment that is registered under section 510 as required by section 503B(a)(2)(C).
Specifically,
On 03/21/2017, the following bulk drug substance manufacturer was identified as not being registered with the FDA:
redacted (b)(4) I 1
The inositol raw ingredient is used in the production of the following finished products:
• Methionine/Inositol/Choline (MIC) 25/50/50 mg/ml 30m! • MIC with Cyanocobalamin 25/50/50/1 mg/ml30 ml • MIC with Cyanocobalamin 25/50/50/1 mglml4 ml
Inspection Sep 9, 2019 to Sep 19, 2019: 3 observations
- Firm on the cover
- AnazaoHealth Corporation, 7465 W Sunset Rd Ste 1200, Las Vegas, NV 89113-194 4
- FEI number
- 3011152407
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 19701 Fairchild Irvine, CA 92612-2445
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Specifically,
A) Following the cleaning of classified laminar flow hoods/biosafety cabinets and clean rooms, your firm does not require a visual inspection to check that the cleaning has been completed and that it was effective. With any type of cleaning there needs to be some type of verification process in place.
During inspection walk-through on September 91 \ I noted the following:
{I>) (4I
tb) (4) 1) An accumulation of cleaning residue from present and past cleaning . was found in LFH <Redacted B4> Cleanroom The residue was located in the back, right hand comer of the LFH <Redacted B4> (or( <Redacted B4> In addition, small cracks/fractures (less than the size of a Washington quarter) were observed in the <Redacted B4> side • paneling • <Redacted B4> LFHs # <Redacted B4> and # <Redacted B4> .
2 ) A small feel of plastic (1/2-inch x 1/8 inch) was observed stuck in the <Redacted B4> front grill of BSC # <Redacted B4> Cleanroom <Redacted B4> ...
Observation 2
~~;( The flow of components, drug product containers, closures and in-process materials -through the building is not designed to prevent contamination.
~¥' Specifically,
<Redacted B4> your sterile compounding clean rooms <Redacted B4> have <Redacted B4> the ISO 7 buffer rooms to unclassified work spaces. Equipment and components are <Redacted B4> prior to and during sterile production.
These <Redacted B4> are not designed with interlocking mechanisms to prevent cross-contamination of the adjoining spaces <Redacted B4> door at a time can open.
Observation 3
Bulk drug substances used by your outsourcing facility to compound drug products are not each manufactured by an establishment that is registered under section 510 of the FDCA as required by section 503(a)(2)(C).
Specifically,
Although you are receiving bulk drug substances from FDA-registered suppliers, you have neither verified these components are manufactured in an FDA-registered establishment nor established a supplier quality agreement that ensures the component's pedigree. An example of suppliers and components with insufficient quality agreements, include: <Redacted B4> <Redacted B4>
- (b) (4)
Linked 483s whose text is not shown
- Sep 23, 2024: FDA document 185396: its numbered observations could not be read reliably from the PDF text.
- Jul 29, 2022: FDA document 163365: its numbered observations could not be read reliably from the PDF text.
- Apr 28, 2017: FDA document 104822: the PDF is a scanned image with no readable text.
- Jul 23, 2015: FDA document 91234: its numbered observations could not be read reliably from the PDF text.
GLP-1 records in this index
No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (AnazaoHealth Corporation). That is not a finding beyond this index’s search.
The AnazaoHealth Corporation pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.
FDA NDC listings
FDA’s NDC Directory files, read Nov 15, 2026, list 2 products naming tirzepatide under the labeler name “AnazaoHealth Corporation”, matched to this facility page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (2). The compounded product reports cover FDA reporting periods 2025-1 to 2025-1.
FDA’s NDC files name the labeler, not the site, so a firm with more than one location shows the same listings on each location’s page.
| Reporting periods | ||||||||
|---|---|---|---|---|---|---|---|---|
| 72682-1205 | Tirzepatide 5mg/mL 2mL | Tirzepatide 5mg/mL Injection 2mL | INJECTION | SUBCUTANEOUS | 5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 | Compounded drugs |
| 72682-1220 | Tirzepatide 20mg/mL 2mL | Tirzepatide 20mg/mL 2mL | INJECTION | SUBCUTANEOUS | 20 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 | Compounded drugs |
FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.
FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- FDA National Drug Code Directory (download files)
- FDA: NDC product file definitions
- openFDA drug NDC endpoint (count cross-check)
Records last pulled Nov 15, 2026. Every entry links to the original public record.